Abstract: A method of designing a D-polypeptide that binds with an L-target protein can include: identifying a polypeptide target having L-chirality; determining hotspot amino acids of a polypeptide ligand having L-chirality that have binding interactions with the L-target protein; determining transformations of side chains of the hotspot amino acids that retain the binding interactions with the target; generating inversed hotspot amino acids with chirality opposite to the one of the target; identifying a polypeptide having inverse chirality from the target protein, on which a combination of inversed hotspot amino-acid can be grafted without significantly changing their interactions with the target. The designed ligands can be processed and converted to D-ligands that bind with the L-target protein.

Abstract: Aspects of the present disclosure provide methods and apparatuses for estimating a biometric parameter using multiple sensors. As described herein, multiple sensors are strategically used to output with increased confidence a biometric parameter. Multiple sensors are strategically used to save power while determining an accurate biometric estimation. Additionally, multiple sensors are used to detect and categorize a sleep apnea event.

Abstract: Techniques for user authentication via in-ear acoustic measurements are disclosed. An in-ear device emits an acoustic signal and detects an otic response to the acoustic signal. A user signature is generated based at least on the otic response to the acoustic signal. The user signature is compared with a reference signature, to determine whether the in-ear device has changed users.

Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: A method of designing a D-polypeptide that binds with an L-target protein can include: identifying a polypeptide target having L-chirality; determining hotspot amino acids of a polypeptide ligand having L-chirality that have binding interactions with the L-target protein; determining transformations of side chains of the hotspot amino acids that retain the binding interactions with the target; generating inversed hotspot amino acids with chirality opposite to the one of the target; identifying a polypeptide having inverse chirality from the target protein, on which a combination of inversed hotspot amino-acid can be grafted without significantly changing their interactions with the target. The designed ligands can be processed and converted to D-ligands that bind with the L-target protein.

Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: A user interaction system (1) is provided that comprises an electrical apparatus (10), a beacon (16) that radiates a photon radiation (R16), a portable pointing device (12) operable by a user for pointing to a region in space (20), which portable pointing device includes a camera (122) connected thereto for obtaining images from said space and a digital signal processor (14). The digital signal processor (14) is capable of receiving and processing the images, and of transmitting user interface information, derived by processing the images, to the electrical apparatus.

Abstract: The present invention relates to a process for drying particulate polymers, comprising the steps of: a) providing a particulate polymer comprising from 60 wt % to 90 wt % of at least one solvent based on the total weight of particulate polymer and solvent, b) mechanically predrying the particulate polymer to a content of the at least one solvent of from 20 wt % to 50 wt % based on the total weight of particulate polymer and solvent, wherein the mechanical predrying in step b) is carried out with a roller press, and c) end-drying the particulate polymer to a content of the at least one solvent of from 0 wt % to 15 wt % based on the total weight of particulate polymer and solvent, wherein the particulate polymer is a polymer comprising repeating units of formulae I, II and/or III The present invention further relates to a process for working up particulate polymers.

Abstract: Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Abstract: The invention relates to a method for producing and using a solid sodium diformate having a high formic acid content, to the use thereof in animal foods in the form of an acidifier, preservatives, ensilage auxiliary agents, fertilizers, and a growth and productivity-stimulating agent and the inventive animal food additives containing sodium diformate.

Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.

Abstract: A process for the preparation of a spray-dried powder containing at least one glycine-N,N-diacetic acid compound of a formula MOOC—CHR—N(CH2COOM)2, where R is a C1-12-alkyl and M is an alkali metal, the process including: preparing an aqueous solution containing the glycine-N,N-diacetic acid compound; concurrently passing the aqueous solution and air into a spray-drying apparatus; atomizing the aqueous solution by feeding the aqueous solution onto a rotating disk or by compressing the aqueous solution with a pump to a pressure of ?20 bar absolute, to obtain fine liquid droplets; and drying the droplets, to obtain the spray-dried powder, where a temperature gradient between the aqueous solution and the air is in a range from 70 to 350° C., and a content of the glycine-N,N-diacetic acid compound in the aqueous solution is ?84% by weight, based on a total weight of the dry mass.

Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.

Abstract: The invention relates to a method for producing and using a solid sodium diformate having a high formic acid content, to the use thereof in animal foods in the form of an acidifier, preservatives, ensilage auxiliary agents, fertilizers, and a growth and productivity-stimulating agent and the inventive animal food additives containing sodium diformate.

Abstract: The invention relates to a method for producing and using a solid sodium diformate having a high formic acid content, to the use thereof in animal foods in the form of an acidifier, preservatives, ensilage auxiliary agents, fertilizers, and a growth and productivity-stimulating agent and the inventive animal food additives containing sodium diformate.

Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.

Abstract: The invention relates to a method for producing and using a solid sodium diformate having a high formic acid content, to the use thereof in animal foods in the form of an acidifier, preservatives, ensilage auxiliary agents, fertilizers, and a growth and productivity-stimulating agent and the inventive animal food additives containing sodium diformate.